Tackling the remaining challenges of multiple sclerosisWith Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond Share XTackling the remaining challenges of multiple sclerosishttps://pharmaphorum.com/r-d/views-analysis-r-d/tackling-the-remaining-challenges-of-multiple-sclerosis/
Merck and Pfizer’s Bavencio approved for renal cell carcinomaMerck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta Share XMerck and Pfizer’s Bavencio approved for renal cell carcinomahttps://pharmaphorum.com/news/merck-and-pfizers-bavencio-approved-for-renal-cell-carcinoma/
German Merck shows new data backing BTK drug evobrutinib in MSGermany’s Merck KGaA has announced new mid-stage data that it says support further studies into its BTK inhibitor Share XGerman Merck shows new data backing BTK drug evobrutinib in MShttps://pharmaphorum.com/news/german-merck-shows-new-data-backing-btk-drug-evobrutinib-in-ms/
Merck KGaA signs another AI dealMerck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative Share XMerck KGaA signs another AI dealhttps://pharmaphorum.com/news/merck-kgaa-signs-another-ai-deal/
Merck KGaA admits to ‘challenging’ 2018, as currencies hit salesGermany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency headwinds and Share XMerck KGaA admits to ‘challenging’ 2018, as currencies hit saleshttps://pharmaphorum.com/news/merck-kgaa-admits-to-challenging-2018-as-currencies-hit-sales/
GSK bolts-on immuno-oncology candidate with €3.7bn Merck dealGlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an Share XGSK bolts-on immuno-oncology candidate with €3.7bn Merck dealhttps://pharmaphorum.com/news/gsk-bolts-on-immuno-oncology-candidate-with-e3-7bn-merck-deal/
Vertex licenses back CRISPR compounds from German MerckUS pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from Share XVertex licenses back CRISPR compounds from German Merckhttps://pharmaphorum.com/news/vertex-licenses-back-crispr-compounds-from-german-merck/
Merck KGaA signs China digital health deal with TencentGermany’s Merck KGaA has signed a collaboration with Tencent to develop digital healthcare services in China. Darmstadt-based Merck’s Share XMerck KGaA signs China digital health deal with Tencenthttps://pharmaphorum.com/news/merck-kgaa-signs-china-digital-health-deal-with-tencent/
Merck KGaA links with AI firm to iron out side-effects during R&DGermany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) Share XMerck KGaA links with AI firm to iron out side-effects during R&Dhttps://pharmaphorum.com/news/merck-kgaa-links-with-ai-firm-to-iron-out-side-effects-during-rd/
